PocDoc

What PocDoc does

PocDoc is a Cambridge, UK-based digital health company that operates a smartphone-based blood testing platform for cardiovascular, metabolic, and renal disease screening. Its core product enables users to perform diagnostic blood tests — initially cholesterol testing for cardiovascular risk — using a smartphone and a connected test kit, producing results without requiring traditional laboratory infrastructure. The platform is positioned as a decentralised diagnostic tool for cardiovascular and chronic disease early detection.

The company generates revenue primarily through contracts with the UK National Health Service for cholesterol testing, with secondary revenue from participation in community health screening programmes. Notable deployments include the Thames Freeport Health Bus, an eight-week mobile screening pilot launched in January 2026 across Barking & Dagenham, Havering, and Thurrock, which expanded the company's service scope into diabetes and hypertension testing. Customer acquisition relies on direct enterprise sales to the NHS, event-driven community screening, and third-party industry recognition (CB Insights Top 50 Digital Health 2025, ranked 46th globally; Digital Health 50 list) rather than traditional consumer marketing.

PocDoc has raised approximately $13.3 million in disclosed funding across multiple rounds, including a $3.2 million seed in January 2022 (Forward Partners, MMC Ventures), a $3.07 million seed extension in March 2023 (Forward Partners, MMC Ventures, Simplyhealth), and a $6.19 million pre-A in November 2024 led by Molten Ventures, MMC Ventures, and Simplyhealth Ventures, with Meridian Health Ventures participating. The company is led by CEO and co-founder Steve Roest, Chief Strategy Officer and co-founder Kiran Roest, Head of R&D and co-founder Vladimir Gubala, and CTO Robin Matthews. Following its November 2024 pre-A, PocDoc announced plans for international expansion.

Name

PocDoc

Legal name

PocDoc

Website

https://pocdoc.co

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

PocDoc is a Cambridge, UK-based digital health company that operates a smartphone-based blood testing platform for cardiovascular, metabolic, and renal disease screening, serving the NHS and community health screening programmes.

Ownership category

akta.pro rank

Product category

Digital Health Diagnostics

NAICS

Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Testing Laboratories (8734), Services-Medical Laboratories (8071)

akta.pro primary industry

Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK)

akta.pro secondary industries

Cardiac & Coagulation POCT (Troponin, BNP, INR/aPTT, D-dimer) (HLAHAOAC), Blood Glucose & Metabolic POCT (Glucose, Ketones, Lactate) (HLAHAOAB), Point-of-Care (POC) & Rapid Diagnostics (near-patient, lateral flow) (HLAAALAG)

Keywords

• Digital health diagnostics
• Cardiovascular screening
• Smartphone diagnostics
• Point-of-care testing
• Cholesterol testing

Headquarters

HQ city

Cambridge

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. NHS Contracts: Revenue generated through contracts with the UK National Health Service for cholesterol testing services, deploying digital diagnostics outside traditional healthcare settings.
2. Healthcare Screening Services: Revenue from participating in community health screening programmes, providing mobile diagnostic testing services for conditions such as diabetes and hypertension.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

PocDoc is a Cambridge, UK-based health-tech company that has developed a smartphone-based quantitative cardiovascular blood test platform. The system uses a proprietary test strip combined with a companion smartphone app to measure cardiovascular risk markers — including total cholesterol, HDL/LDL cholesterol, HbA1c, triglycerides, and full lipid panel — delivering lab-grade results in approximately 10 minutes outside traditional laboratory settings.

Product overview

PocDoc offers a digital health diagnostics platform focused on cardiovascular disease screening. The core product is a smartphone-based blood testing system that allows users to perform cholesterol and cardiovascular diagnostic tests outside traditional healthcare settings. The company has secured NHS contracts to increase access to cholesterol testing, positioning its platform as a tool for decentralized healthcare delivery.

Differentiator

Problem solved

Functional benefit

Products and services

• PocDoc Cardiovascular Blood Test System End-to-end smartphone-based cardiovascular diagnostic platform combining a proprietary blood test strip with a mobile app that produces lab-grade lipid panel, cholesterol, and HbA1c results in approximately 10 minutes. Designed for use by healthcare providers in NHS screening programmes, community pharmacies, and individual consumers purchasing through retail channels such as Holland & Barrett.
• PocDoc NHS Cardiovascular Disease Prevention Service Enterprise deployment of the PocDoc platform for the NHS national CVD prevention programme, enabling decentralized cardiovascular risk assessment in community settings rather than traditional clinical laboratories.

Quantifiable outcome

• Improves health outcomes through early detection of cardiovascular disease
• +1 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Four partnerships are on record, tiered flagship and core.

• Thames FreeportflagshipStrategic or Co-development Partner · 12 January 2026PocDoc participates in Thames Freeport's Healthcare Innovation Lab as part of the eight-week mobile health screening pilot programme launched on 12 January 2026. The partnership integrates PocDoc into the Thames Freeport delivery consortium alongside Avencera and other healthtech companies, deploying digital health diagnostics in community settings.
• L MarkscoreStrategic or Co-development Partner · 1 January 2026L Marks, in partnership with Avencera, launched the Thames Freeport Health Bus Screening Programme. L Marks is the innovation partner driving the health screening initiative that incorporates PocDoc's diagnostic platform.
• AvenceracoreStrategic or Co-development Partner · 1 January 2026Avencera serves as part of Thames Freeport's delivery consortium, partnering with L Marks to deliver the mobile health screening pilot programme integrating PocDoc and six other healthtech companies.
• NHScoreOthersPocDoc has secured NHS contracts to deploy its digital health diagnostics platform, focusing on increasing access to cholesterol testing outside traditional healthcare settings.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Thriva: Thriva offers finger-prick blood testing kits shipped to consumers with results reviewed by clinicians, including cardiovascular and metabolic markers. It is a direct peer because both companies deliver decentralized blood-based diagnostics for cardiovascular and metabolic health, though via different delivery models (postal kit vs. smartphone-native).
• MyHealthChecked: MyHealthChecked is a UK-based digital diagnostics company offering at-home blood testing kits and results via a digital platform. It is comparable to PocDoc in serving UK consumers and health systems with home-based blood diagnostics for chronic-disease monitoring.
• Healthy.io: Healthy.io provides smartphone-based at-home diagnostic testing, including urinalysis and kidney disease screening, delivered through health systems and pharmacies. It is a direct peer to PocDoc because both turn the smartphone camera into a clinical-grade point-of-care diagnostic device for chronic-disease screening.

Regional players

• Skin Analytics: Skin Analytics is a UK-based digital health company using AI on smartphone images for dermatology triage, with NHS deployment. It is a regional peer because both are UK digital health companies that have secured NHS contracts for smartphone-based decentralized diagnostics, even though they address different clinical conditions.

Emerging players

• CardioSignal: CardioSignal offers smartphone-based detection of heart disease using motion-sensor data without additional hardware. It is an emerging-player peer because both companies pursue smartphone-native cardiovascular screening, though CardioSignal uses accelerometer/gyroscope signals rather than blood-based biomarkers.
• AliveCor (KardiaMobile): AliveCor's KardiaMobile is a smartphone-connected ECG device used for cardiac screening and remote monitoring. It is an emerging-player peer because both target decentralized cardiovascular screening via smartphone-coupled hardware, though AliveCor focuses on ECG rather than blood biomarkers.

Broad incumbents

• Abbott (i-STAT / Point-of-Care): Abbott's i-STAT and Piccolo systems are established point-of-care blood diagnostics platforms used in NHS hospitals, urgent care, and physician offices. It is a broad incumbent peer because it competes for the same cardiac and metabolic POCT budgets PocDoc targets, though via dedicated hardware rather than a smartphone-native workflow.
• Cleveland HeartLab (Quest Diagnostics): Quest Diagnostics (through Cleveland HeartLab) provides advanced cardiovascular disease testing panels used by clinicians for risk assessment. It is a broad incumbent peer because it competes for cardiovascular diagnostics spend with deeper lab infrastructure but lacks PocDoc's decentralized, smartphone-native workflow.
• Siemens Healthineers (Point-of-Care): Siemens Healthineers offers the epoc and DCA Vantage point-of-care blood analyzers deployed across NHS trusts and global health systems. It is a broad incumbent peer because it serves the same cardiovascular and metabolic POCT use cases PocDoc addresses, but through enterprise hardware sold to hospital systems.
• Roche Diagnostics: Roche Diagnostics provides cobas Liat and other POCT platforms widely used by health systems for cardiac and metabolic markers. It is a broad incumbent peer because it competes for the same NHS and broader health-system cholesterol and cardiac-marker testing budget with established hardware.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/mypocdoc

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds6 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PocDoc